ABBV-8E12 ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
5	進行性核上性麻痺	9
7	大脳皮質基底核変性症	1

5. 進行性核上性麻痺

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-001590-16-DE (EUCTR)	02/07/2019	11/01/2019	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	Progressive Supranuclear Palsy (PSP) MedDRA version: 20.0;Level: PT;Classification code 10036813;Ter ...	Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12 Product Code: ABBV-8E12 Other descriptive nam ...	AbbVie Deutschland	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 2	United States;Canada;Australia;Germany
2	EUCTR2016-001635-12-ES (EUCTR)	04/07/2018	10/05/2018	A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12in Subjects ...	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Toler ...	Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Pro ...	Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12 Other descriptive name: ABBV-8E12 Product Code: ...	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 2	United States;Canada;Spain;Australia;Germany;Italy
3	EUCTR2017-001590-16-IT (EUCTR)	27/04/2018	04/11/2020	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) - na	Progressive Supranuclear Palsy (PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Ter ...	Product Name: na Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	United States;Canada;Australia;Germany;Italy
4	NCT03413319 (ClinicalTrials.gov)	April 17, 2018	23/1/2018	Extension Study of ABBV-8E12in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Stud ...	Extension Study of ABBV-8E12in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Stud ...	Progressive Supranuclear Palsy (PSP)	Drug: ABBV-8E12	AbbVie	NULL	Completed	18 Years	N/A	All	3	Phase 1	United States
5	NCT03391765 (ClinicalTrials.gov)	January 24, 2018	2/1/2018	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)	Progressive Supranuclear Palsy (PSP)	Drug: ABBV-8E12;Drug: Placebo solution for IV infusion on Day 15	AbbVie	NULL	Terminated	40 Years	N/A	All	142	Phase 2	United States;Australia;Canada;Italy;Japan;France
6	EUCTR2016-001635-12-DE (EUCTR)	23/11/2017	20/02/2017	A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12in Subjects ...	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Toler ...	Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Pro ...	Product Code: ABBV-8E12 Product Code: ABBV-8E12 Other descriptive name: ABBV-8E12	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 2	United States;Canada;Spain;Australia;Germany;Italy
7	EUCTR2016-001635-12-FR (EUCTR)	26/10/2017	17/07/2017	A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12in Subjects ...	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Toler ...	Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Pro ...	Product Code: ABBV-8E12	AbbVie Deutschland GmbH & Co. KG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 2	Canada;United States;Italy;France;Australia;Germany;Spain
8	EUCTR2016-001635-12-IT (EUCTR)	31/05/2017	05/02/2018	A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12in Subjects ...	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Toler ...	Progressive Supranuclear Palsy MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Pro ...	Product Name: ABBV-8E12 Product Code: ABBV-8E12 INN or Proposed INN: ABBV-8E12	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 2	United States;Canada;Australia;Italy
9	NCT02985879 (ClinicalTrials.gov)	December 12, 2016	1/12/2016	A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12in Subjects With ...	A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Toler ...	Progressive Supranuclear Palsy	Drug: Placebo;Drug: ABBV-8E12	AbbVie	NULL	Terminated	40 Years	N/A	All	378	Phase 2	United States;Australia;Canada;France;Germany;Italy;Japan;Spain

First Previous1Next Last

先頭へ

7. 大脳皮質基底核変性症

臨床試験数 : 16 / 薬物数 : 28 - (DrugBank : 13) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 38

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03744546 (ClinicalTrials.gov)	November 26, 2018	14/11/2018	Expanded Access to ABBV-8E12	Expanded Access to ABBV-8E12	Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)	Drug: ABBV-8E12	AbbVie	NULL	No longer available	40 Years	N/A	All			NULL

First Previous1Next Last

先頭へ